Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CX 2029

Next Previous
Drug Profile

CX 2029

Alternative Names: ABBV-2029; ABBV-CX-2029; CD71 probody drug conjugate - CytomX Therapeutics; CX-2029

Latest Information Update: 05 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CytomX Therapeutics
  • Developer AbbVie; CytomX Therapeutics
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Cell cycle inhibitors; Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diffuse large B cell lymphoma; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours

Most Recent Events

  • 21 Mar 2023 AbbVie terminates the licensing and collaboration agreement with CytomX Therapeutics for the development of CX 2029
  • 05 Jan 2023 Efficacy and adverse events data from a phase II trial in Non-small cell lung cancer, Head and neck cancer, Gastric cancer and Oesophageal cancer released by CytomX Therapeutics
  • 14 Jul 2022 CytomX Therapeutics completes enrolment in its phase II trial for Non-small cell lung cancer, Head and neck cancer, Gastric cancer and Oesophageal cancer in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top